Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12552743-B2

Patent

Publication Date

2026-02-17

Expiration Date


Abstract

Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.

Core Innovation

The disclosure describes a method for preparing an oligonucleotide comprising one or more phosphoramidate internucleotidic linkages using a specified phosphoramidite compound and a formula III oligonucleotide. The phosphoramidite compound or a salt thereof comprises a G2 group having an electron-withdrawing group. The preparation process comprises contacting the formula III oligonucleotide with a base substantially absent of water after achieving target oligonucleotide length and before deprotection and cleavage [procedural detail omitted for safety].

The described embodiments encompass chirally controlled oligonucleotides containing neutral or non-negatively charged internucleotidic linkages with stereoselective Rp or Sp configurations at linkage phosphorus. These compositions encompass modified nucleobases, sugar modifications, terminal linkers, phosphorothioate modifications, and chiral auxiliaries designed for removal during synthesis. Multivalent conjugate architectures incorporate targeting moieties such as lipids, carbohydrates, or peptides attached through cleavable or configurable linkers.

Documented embodiments comprise chirally controlled oligonucleotide compositions evaluated for gene knockdown and dystrophin exon skipping. Reported targets comprise Malat1, C9orf72, and DMD exons including exons 23, 45, 51, and 53. Because the background section is omitted from the provided text, the specific technical problem addressed in the background is not explicitly described in the patent.

Claims Coverage

The provided relevant claims identify one independent claim comprising two inventive features directed to the preparation of phosphoramidate-containing oligonucleotides.

Preparation of phosphoramidate-containing oligonucleotides with a specified phosphoramidite compound

The claim covers a method for preparing an oligonucleotide comprising one or more phosphoramidate internucleotidic linkages using a specified phosphoramidite compound, or salt thereof, and a formula III oligonucleotide, wherein G2 comprises an electron-withdrawing group.

Base contact under substantially water-absent conditions

The claim specifies contacting the formula III oligonucleotide with a base substantially absent of water after the target oligonucleotide length is achieved and before deprotection and cleavage [procedural detail omitted for safety].

The independent claim combines a specified phosphoramidite compound having an electron-withdrawing group at G2 with a timed, substantially water-absent base contact stage to prepare an oligonucleotide comprising phosphoramidate internucleotidic linkages.

Stated Advantages

Higher crude yields and purities can reduce downstream purification and manufacturing costs.

Coupling and modifying steps provide high diastereoselectivity in the stereoselective preparation of oligonucleotides.

Alternative chiral auxiliaries provide improved reaction compatibility and product quality.

Neutral or non-negatively charged internucleotidic linkages provide beneficial effects on cellular uptake, endosomal escape, and target hybridization.

Reported over 15-fold IC50 improvement for Malat1 knockdown versus comparators for WV-11533.

Reported substantial DMD exon skipping, C9orf72 transcript reduction, and oligonucleotide stability.

Little TLR9 activation reported for selected tested designs.

Base treatment removes chiral auxiliaries and reduces unintended natural-phosphate by-products at P—N= linkages, with reduced shorter-sequence impurities.

Reduced treatment time, reduced temperature, and reduced desulfurization or support cleavage.

Increased dystrophin exon skipping for exons 45, 51, or 53, with example compositions demonstrating substantially greater activity than Drisapersen- or Eteplirsen-related controls.

Additional guanidine-containing or neutral-linkage moieties and lipid components intended to improve delivery and potentially increase exon-skipping efficiency.

Documented Applications

Preparation and stereoselective synthesis of oligonucleotides containing one or more phosphoramidate internucleotidic linkages, including chirally controlled, neutral, or non-negatively charged linkages.

Preparation of oligonucleotide dimer 1018 using sulfonyl phosphoramidite 1017.

Gene knockdown and modulation of transcript levels and transcript splicing, including antisense oligonucleotides and siRNA targeting Malat1 and C9orf72.

Exon skipping to restore the dystrophin reading frame across multiple dystrophin exons in Duchenne muscular dystrophy, including exons 23, 45, 51, 51–55, and 53 in patient-derived myoblasts and animal models.

Combination treatments for Duchenne muscular dystrophy, Becker muscular dystrophy, related muscular dystrophies, and dystrophin-related CNS disorders with utrophin modulators, splicing regulators, antifibrotic treatments, steroids, gene or cell therapies, and supportive treatments.

Delivery of dystrophin-targeting oligonucleotides to muscle and extrahepatic tissues utilizing pharmaceutical compositions, targeting ligands, and conjugates, including GalNAc- and lipid-containing constructs.

Quantification of dystrophin splice variants using a unique molecular identifier-based long-read assay.

Functionalization of amino-terminated oligonucleotides with cholesterol, L-carnitine, carbohydrate-rich, anisamide, sulfamoyl, and lipid-containing conjugates.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.